2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Renal Cell
27
Neoplasms
14
Neoplasm Metastasis
14
Glioblastoma
14
Prostatic Neoplasms
13
Lymphoma, Mantle-Cell
11
Breast Neoplasms
11
Brain Neoplasms
11
Sarcoma
10
Lymphoma, Non-Hodgkin
10
Kidney Neoplasms
10
Endometrial Neoplasms
10
Melanoma
9
Gliosarcoma
8
Multiple Myeloma
7
Glioma
7
Ovarian Neoplasms
6
Carcinoma, Hepatocellular
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Oligodendroglioma
5
Lymphoma, Follicular
5
Lymphoma
5
Hodgkin Disease
5
Central Nervous System Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Astrocytoma
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
4
Rhabdomyosarcoma
4
Interventions
Specimen Handling
3
Nivolumab
3
olaparib
2
durvalumab
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Carboplatin
2
CTLA-4 Antigen
2
temsirolimus
1
sintilimab
1
serabelisib
1
sapanisertib
1
rucaparib
1
pembrolizumab
1
palbociclib
1
defactinib
1
copanlisib
1
ceralasertib
1
cediranib
1
capivasertib
1
cabozantinib
1
adavosertib
1
Therapeutics
1
Taxes
1
Restraint, Physical
1
Radiation, Ionizing
1
Radiation
1
RO5126766
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Endometrioid
×
temsirolimus
×
Clear all
NCT02093598
2020-11-27
POEM
MedSIR
Phase 2
Completed
10 enrolled